Next Biomedical

Name

Next Biomedical

Legal name

NEXTBIOMEDICAL CO., LTD.

Website

https://nextbiomedical.co.kr

Company type

Private

Founded year

2019

Operating status

Operating

Headcount range

51–100 employees

Ownership category

akta.pro rank

Product category

Medical Devices — Polymer-Based Therapeutics

NAICS

Surgical and Medical Instrument Manufacturing (339112)

SIC

Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Thrombectomy, Embolic Protection & Stroke Intervention Devices (HLAHAFAJ)

Keywords

• Polymer drug delivery
• Embolization microspheres
• Endoscopic hemostasis devices
• Biodegradable medical implants
• Vascular embolization agents

Headquarters

HQ city

Incheon

HQ country

South Korea

HQ region

Asia

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Supply Chain, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Medical Device Sales: Sale of proprietary medical devices including hemostasis products (Nexpowder) and embolization agents (Nexsphere, Nexsphere-F, NexGel). Products sold through direct sales team and distribution partners globally.
2. Product Distribution Partnerships: Revenue generated through exclusive distribution agreements with international partners. Asahi Intecc distributes Nexsphere-F in Japan, leveraging their global vascular device network.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels4 records

Core offering

Next Biomedical develops and commercializes innovative polymer-based medical devices for gastrointestinal hemostasis and vascular embolization. Its product portfolio spans endoscopic hemostatic powders and patches for GI bleeding, plus a family of resorbable and drug-eluting microspheres for tumor embolization, musculoskeletal pain, and locoregional drug delivery. The company leverages proprietary adhesive polymer, microparticle, and drug-device combination platforms across hemostasis and embolization therapeutic areas.

Product overview

Next Biomedical is a medical device company developing innovative polymer-based therapeutics across three core technology platforms: adhesive polymers, multifunctional microspheres, and drug-device combinations. The product portfolio spans two main therapeutic areas: GI endoscopic hemostasis (Nexpowder™ for bleeding control, Nexpowder-STM with drug-loading capability, Nexwafer™ for peritoneal cancer, Nexpatch™ for pleural sealing) and embolic agents (NexGel resorbable gelatin microparticles, Nexsphere™ with adjustable degradation, Nexsphere-F™ for rapid pain embolization, Nexsphere-D™ drug-eluting beads for liver cancer, NexGCM™ sustained-release microspheres for arthritis, and Guardgel). The company commercializes products individually by country and is pursuing global licensing discussions for select products.

Differentiator

Problem solved

Functional benefit

Brands

• Nexsphere-F: Fast-resorbable microsphere for embolization, used for musculoskeletal pain treatment including knee osteoarthritis
• Nexsphere
• NexGel
• Nexpowder
• Nexpowder-S
• Nexwafer
• Nexpatch
• NexGCM
• Nexsphere-D
• Nexsphere-F

Products and services

• Nexpowder Endoscopic hemostatic powder applied via endoscope to control non-variceal upper gastrointestinal bleeding, including peptic ulcer hemorrhage and post-procedural bleeding. For gastroenterology departments and endoscopy centers performing therapeutic endoscopic procedures.
• Nexsphere Adjustable degradation time vascular embolization therapeutic microsphere made from biodegradable natural polymer, indicated for liver cancer, uterine fibroids, and arterial bleeding. For interventional radiologists performing embolization procedures.
• Nexsphere-F Rapidly resorbable microsphere for pain embolization using fast-absorbing gelatin-based microparticles, indicated for musculoskeletal pain embolization including knee osteoarthritis pain. For interventional radiologists and orthopedic specialists.
• NexGel Resorbable gelatin hydrophilic intravascular embolization prosthetic injected via catheter with contrast agent to temporarily occlude blood vessels during embolization. Features high elasticity and strong cohesion, available in particle sizes from 150 to 3500 micrometers. For interventional radiologists.
• Nexwafer Drug-loaded adhesive wafer applied to residual tumor sites or unresectable areas following cytoreductive surgery for peritoneal cancer treatment. For surgical oncologists and cancer treatment centers.
• Nexpatch Pleural patch made from chitosan and gelatin-based double-networking polyampholyte hydrogel for air leakage and tissue damage repair in pneumothorax and lung resection procedures. For thoracic surgeons.
• Nexsphere-D Drug-eluting bead for liver cancer treatment. Biodegradable natural polymer microsphere loaded with anticancer drugs that simultaneously embolizes tumor-feeding vessels while delivering chemotherapy. For interventional radiologists and oncologists.
• NexGCM Sustained-release drug-delivery microsphere for arthritis treatment. Temperature-responsive polymer microsphere loaded with steroids, providing 3 to 6 months of controlled drug release for joint arthritis treatment. For orthopedic specialists and rheumatologists.

Quantifiable outcome

• Nexsphere-F received Health Canada approval for musculoskeletal pain embolization
• +1 more outcomes

Named customers1 record

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Two partnerships are on record, tiered core.

• Asahi Intecc Co., Ltd.coreChannel Partner/ Reseller/ Distributor · 10 April 2026Exclusive distribution agreement for Nexsphere-F embolization device in Japan. Asahi Intecc, a global vascular device supplier, will conduct clinical trials and support regulatory/market entry for Nexsphere-F in the Japanese market.
• MedtroniccoreChannel Partner/ Reseller/ DistributorNexpowder endoscopic hemostatic product distributed through Medtronic globally. Medtronic is a leading global medical device company providing distribution and market access for the product.

Scale indicators3 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• Cook Medical: Pioneer in embolization products (PVA particles, coils, hydrogels) and one of the largest players in endoscopic hemostasis devices. Broad portfolio competes with both Nexpowder (GI bleeding) and Nexsphere (vascular embolization) across interventional radiology and gastroenterology.
• Guerbet: Specialist in contrast agents and embolic products including Lipiodol for vascular embolization and interventional oncology. Competes with Next Biomedical's embolic agents in interventional radiology workflows.
• Boston Scientific: Global medical device leader with the Embosphere and Contour embolic bead franchises plus LC Bead drug-eluting beads for oncology. Directly competes with Nexsphere and Nexsphere-D across peripheral and interventional oncology embolization, with deep physician relationships and bundled product portfolios.
• Terumo: Through its Terumo Interventional Systems division, manufactures drug-eluting beads (DEBs) and microspheres for TACE and interventional oncology. Competes directly with Nexsphere-D in liver cancer embolization and overlaps in vascular embolization.
• Sirtex Medical: Specialist in SIR-Spheres Y-90 resin microspheres for selective internal radiation therapy (SIRT) of liver cancer. Directly comparable targeted liver cancer embolization franchise competing with Nexsphere-D in interventional oncology.
• Merit Medical Systems: Manufacturer of Embosphere microspheres and HepaSphere drug-eluting beads for embolization procedures. Closely comparable embolic bead technology competing head-to-head with Next Biomedical's Nexsphere family in peripheral embolization and interventional oncology.

Emerging players

• Surmodics: Specialist in surface modification coatings and drug-delivery coating technologies for medical devices. Thematically overlaps with Next Biomedical's drug-device combination platform and offers adjacent enabling technology for the broader interventional medical device space.

Broad incumbents

• Penumbra: Focused on vascular thrombectomy and embolization devices including the Ruby coil and LANtern delivery system. Competes in adjacent interventional radiology and vascular procedure workflows where Next Biomedical's embolization products are used.
• Olympus: Global leader in endoscopy and gastrointestinal therapeutic devices, including hemostatic products for GI bleeding. Much broader endoscopy portfolio than Next Biomedical, but competes directly with Nexpowder in the GI hemostasis procedural market.

Regional players

• Genostech: Korean medical device company developing biodegradable implants and drug delivery systems. Regional peer with similar polymer/biomaterials technology focus and comparable stage of commercialization, offering a useful Korean market comparison.

Market position

Strengths5 records

Weaknesses1 record

Competitive moat4 records

Key risks6 records

Customer concentration

• Xx.com/nextbiomedical

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Next Biomedical